LLY

969.62

-3.14%↓

JNJ

236.78

-3.59%↓

ABBV

228.95

-2.31%↓

NVS

159.49

-2.93%↓

AZN

196.22

-2.82%↓

LLY

969.62

-3.14%↓

JNJ

236.78

-3.59%↓

ABBV

228.95

-2.31%↓

NVS

159.49

-2.93%↓

AZN

196.22

-2.82%↓

LLY

969.62

-3.14%↓

JNJ

236.78

-3.59%↓

ABBV

228.95

-2.31%↓

NVS

159.49

-2.93%↓

AZN

196.22

-2.82%↓

LLY

969.62

-3.14%↓

JNJ

236.78

-3.59%↓

ABBV

228.95

-2.31%↓

NVS

159.49

-2.93%↓

AZN

196.22

-2.82%↓

LLY

969.62

-3.14%↓

JNJ

236.78

-3.59%↓

ABBV

228.95

-2.31%↓

NVS

159.49

-2.93%↓

AZN

196.22

-2.82%↓

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Atvērts

3.88 -5.6

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.84

Max

4.21

Galvenie mērījumi
By Trading Economics
Ienākumi	5.5M -28M
Pārdošana	8.2M 13M
Peļņas marža	-208.694
Darbinieki	172
EBITDA	8.7M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+271.19% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 10. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-24M 231M
Iepriekšējā atvēršanas cena	9.48
Iepriekšējā slēgšanas cena	3.88

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. marts 23:39 UTC

Karstas akcijas

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

2026. g. 4. marts 23:20 UTC

Peļņas

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

2026. g. 4. marts 21:43 UTC

Peļņas

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

2026. g. 4. marts 23:48 UTC

Tirgus saruna

Nikkei May Rise After Recent Selloffs -- Market Talk

2026. g. 4. marts 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

2026. g. 4. marts 23:24 UTC

Tirgus saruna

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

2026. g. 4. marts 22:30 UTC

Peļņas

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

2026. g. 4. marts 22:30 UTC

Peļņas

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

2026. g. 4. marts 22:30 UTC

Peļņas

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

2026. g. 4. marts 22:13 UTC

Peļņas

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

2026. g. 4. marts 22:13 UTC

Peļņas

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

2026. g. 4. marts 22:13 UTC

Peļņas

Vermilion Energy 4Q EPS C$2.86 >VET

2026. g. 4. marts 22:04 UTC

Tirgus saruna

RBA Slipping Behind The Curve On Rates -- Market Talk

2026. g. 4. marts 21:53 UTC

Peļņas

Lithium Americas 4Q Rev $66.8M >LAC

2026. g. 4. marts 21:53 UTC

Peļņas

Lithium Americas 4Q Loss/Shr 52c >LAC

2026. g. 4. marts 21:52 UTC

Peļņas

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

2026. g. 4. marts 21:50 UTC

Peļņas

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

2026. g. 4. marts 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 4. marts 21:48 UTC

Peļņas

Webull 4Q Rev $165.2M >BULL

2026. g. 4. marts 21:48 UTC

Peļņas

Webull 4Q EPS 1c >BULL

2026. g. 4. marts 21:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 4. marts 21:45 UTC

Tirgus saruna

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

2026. g. 4. marts 21:40 UTC

Peļņas

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

2026. g. 4. marts 21:36 UTC

Galvenie ziņu notikumi

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

2026. g. 4. marts 21:27 UTC

Peļņas

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

2026. g. 4. marts 21:17 UTC

Tirgus saruna

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

2026. g. 4. marts 21:16 UTC

Peļņas

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

2026. g. 4. marts 21:15 UTC

Peļņas

Broadcom 1Q EPS $1.50 >AVGO

2026. g. 4. marts 21:15 UTC

Peļņas

Broadcom 1Q Net $7.35B >AVGO

2026. g. 4. marts 21:15 UTC

Peļņas

Broadcom 1Q Rev $19.31B >AVGO

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

271.19% augšup

Prognoze 12 mēnešiem

Vidējais 15.33 USD 271.19%

Augstākais 25 USD

Zemākais 10 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.